Targacept buoyed by AZ's commitment to Alzheimer's program

Shares of Targacept ($TGRT) were buoyed this morning by the news that AstraZeneca ($AZN) is committing its support for the experimental Alzheimer's drug AZD1446, which is moving into a midstage study. That's good news for Targacept, which has been forced to concede recently that the first two late-stage studies for a depression drug partnered with AstraZeneca have failed. Release

Suggested Articles

A who’s who of Big Pharmas, including Pfizer, Johnson & Johnson and Merck, have banded together to bolster the development of new antibiotics.

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.